FOCUS ON
March 4, 2021

COVID-19 Vaccines: mRNA Vaccines

Introduction
The novel coronavirus disease (COVID-19) pandemic has stimulated unprecedented efforts to develop vaccines that provide protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).¹

This Focus On is the first in a series on emerging COVID-19 vaccines, intended for health care providers and public health partners. It provides an overview of messenger ribonucleic acid (mRNA) vaccines, including products authorized for use in Canada. This document will be updated as new information becomes available.

The Basics: mRNA Vaccines
mRNA vaccines have emerged as a promising alternative to conventional vaccine platforms.²,³ While efforts to develop a mRNA vaccine were initially limited by the transient nature of mRNA in human cells, major innovations over the last two decades have accelerated mRNA vaccine development.²-⁴

What is mRNA?
Messenger ribonucleic acid (mRNA) is a type of transcript, which is used by our cells to transfer genetic information from DNA to make proteins.²,⁵-⁷

Vaccines work by training our immune system to recognize and respond to infectious agents. For most vaccines, this is accomplished by delivering a weakened or inactivated virus or a component of the virus (such as a specific protein) to the body, which triggers an immune response.²,³ In contrast, mRNA vaccines work by delivering instructions to human cells to produce a viral protein, which is then recognized by the body as foreign.²,⁸ These proteins, known as antigens, use the body’s normal processes to safely produce an immune response. There are two main types of RNA vaccines:

- **Non-replicating (or non-amplifying) RNA vaccines** are the simplest type and consist of mRNA coding for the viral antigen. Our cell machinery is used to make a specific viral antigen and once this is accomplished, the mRNA is cleared.⁹,¹⁰ COVID-19 mRNA vaccines are non-replicating RNA vaccines.³,¹⁰

- **Self-replicating (or self-amplifying) RNA vaccines** consist of an RNA coding for the viral antigen and the virus’ replication machinery, allowing for abundant production of viral antigen.⁹,¹⁰
Mechanism of action and immune response

COVID-19 mRNA vaccines use our normal cell processes to safely produce the SARS-CoV-2 spike glycoprotein antigen, which activates both antibody and cell-mediated immune responses.\(^7,10,11\)

- mRNA vaccines are encapsulated in a lipid coat, commonly referred to as a lipid nanoparticle (LNP), which allows them to easily cross cell membranes into our cells.\(^2-7\)

- Once inside our cells, mRNA is released into the cytoplasm where the body’s cell machinery makes copies of the SARS-CoV-2 spike glycoprotein antigen. The mRNA instructions are then rapidly broken down and disposed of by our cells.\(^3-7,10,11\)

- Next, the SARS-CoV-2 spike glycoprotein antigen is temporarily displayed on the surface of our cells, where it is recognized as foreign and activates B (antibody-mediated) and T (cell-mediated) cells of the immune system.\(^3,10,11\)

- Activation of cell-mediated immune responses are expected to play a central role in providing us with long-term protection.\(^10\) Antibody-mediated responses directed against the SARS-CoV-2 spike glycoprotein are believed to be important for blocking the virus from entering our cells.\(^10\)

Key messages: COVID-19 mRNA vaccines

1. You cannot get COVID-19 from an mRNA vaccine.

mRNA COVID-19 vaccines are non-infectious (they do not contain whole or live SARS-CoV-2); therefore there is no risk of a mRNA vaccine causing COVID-19.\(^3-7\)

2. mRNA vaccines are a new vaccine platform, but not a new technology.

While mRNA therapeutics have been studied for over two decades, recent scientific advancements have improved mRNA stability and delivery which has been important for bringing mRNA vaccines and cancer mRNA therapeutics into clinical use.\(^2,4,6,7\)

3. mRNA vaccines do not affect or interact with our DNA.

Human cells break down and get rid of mRNA as soon as they finish using its instructions. mRNA does not enter the nucleus of human cells, where our DNA is located, eliminating any risk of mRNA interacting with our DNA.\(^2-7,11\)

Advantages and limitations of mRNA vaccines

Recent advances in mRNA vaccine technology offer several advantages over classical vaccine platforms. Rapid and scalable manufacturing as compared to conventional vaccines, allows for quicker vaccine production in response to novel pathogens, such as SARS-CoV-2, or novel SARS-CoV-2 variants of concern (VOC).\(^3,4,11-13\) Additionally, since mRNA vaccines produce both antibody and cell-mediated immune system responses they are anticipated to provide longer-term protection.\(^10\) Finally, mRNA vaccines are non-infectious so there is no risk of infection from the vaccine.\(^3,7,11\) Limitations of mRNA vaccine use relate to vaccine storage and handling requirements, including the need for freezing.
temperatures (due to mRNA being highly labile), and increased reactogenicity (i.e. side effects such as fever, muscle aches and fatigue), relative to some other vaccine platforms.  

COVID-19 mRNA vaccines

In Canada, two COVID-19 mRNA vaccines have been authorized for use under Health Canada’s Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19. Detailed characteristics of each vaccine are outlined in Table 1.

Table 1: Characteristics of COVID-19 mRNA vaccines authorized for use in Canada

<table>
<thead>
<tr>
<th>Vaccine Name</th>
<th>Pfizer Inc. (USA)-BioNTech SE (Germany)</th>
<th>Moderna Inc. (USA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaccine Platform</td>
<td>LNP-encapsulated, non-replicating, nucleoside-modified mRNA vaccine</td>
<td>LNP-encapsulated, non-replicating, nucleoside-modified mRNA vaccine</td>
</tr>
<tr>
<td>Antigenic Target</td>
<td>Pre-fusion SARS-CoV-2 spike (S) glycoprotein</td>
<td>Pre-fusion SARS-CoV-2 spike (S) glycoprotein</td>
</tr>
<tr>
<td>No. of Doses Administered</td>
<td>2 doses</td>
<td>2 doses</td>
</tr>
<tr>
<td>Dosage</td>
<td>30 µg of mRNA per 0.3 mL dose</td>
<td>100 µg of mRNA per 0.5 mL dose</td>
</tr>
<tr>
<td>Adjuvant</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Diluent</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Schedule</td>
<td>Authorized Interval: 21 days (3 weeks)</td>
<td>Authorized interval: 28 days (4 weeks)</td>
</tr>
<tr>
<td></td>
<td>Alternate Interval: 3 weeks to 4 months</td>
<td>Alternate Interval: 4 weeks to 4 months</td>
</tr>
<tr>
<td></td>
<td>Minimum Interval: 19 days</td>
<td>Minimum Interval: 21 days</td>
</tr>
<tr>
<td>Route of Administration</td>
<td>Intramuscular (IM)</td>
<td>Intramuscular (IM)</td>
</tr>
<tr>
<td>Storage Conditions</td>
<td>-80 °C to -60 °C</td>
<td>-25 °C to -15 °C</td>
</tr>
<tr>
<td></td>
<td>-25 °C to -15 °C for up to 2 weeks</td>
<td>Once thawed, 2 °C to 8 °C for up to 30 days</td>
</tr>
<tr>
<td></td>
<td>Once thawed, 2 °C to 8 °C for 5 days</td>
<td>Do not refreeze</td>
</tr>
<tr>
<td></td>
<td>Do not refreeze</td>
<td>Keep vials in original packaging to protect from light</td>
</tr>
<tr>
<td></td>
<td>Keep vials in original packaging to protect from light</td>
<td></td>
</tr>
</tbody>
</table>
References


